Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 4—April 2008
Conference Summary
Peer Reviewed Report Available Online Only

Conference Report on Public Health and Clinical Guidelines for Anthrax

Eric Jacob Stern*, Kristin Broome Uhde*, Sean Vincent Shadomy*Comments to Author , and Nancy E. Messonnier*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Figure

Revisions to the Centers for Disease Control and Prevention (CDC) interim inhalation anthrax screening guidelines proposed by Mayer et al (29), and reviewed by participants in CDC meeting on public health and clinical guidelines for anthrax. For further detail on subsequent algorithm steps see (29). Adapted from (29).

Figure. Revisions to the Centers for Disease Control and Prevention (CDC) interim inhalation anthrax screening guidelines proposed by Mayer et al (29), and reviewed by participants in CDC meeting on public health and clinical guidelines for anthrax. For further detail on subsequent algorithm steps see (29). Adapted from (29).

Main Article

References
  1. Bell  DM, Kozarsky  PE, Stephens  DS. Conference Summary: Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis. 2002;8:2225.PubMed
  2. Walsh  JJ, Pesik  N, Quinn  CP, Urdaneta  V, Dykewicz  CA, Boyer  AE, A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis. 2007;44:96871. DOIPubMed
  3. Jernigan  DB, Raghunathan  PL, Bell  BP, Brechner  R, Resnitz  EA, Butler  JC, Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis. 2002;8:101928.PubMed
  4. Shepard  CW, Soriano-Gabarro  M, Zell  ER, Hayslett  J, Lukacs  S, Goldstein  S, Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis. 2002;8:112432.PubMed
  5. CDC. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2002;51:10246.PubMed
  6. Centers for Disease Control and Prevention. Responding to detection of aerosolized Bacillus anthracis by autonomous detection systems in the workplace. MMWR Morb Mortal Wkly Rep. 2004;53(RR07):112.
  7. Doganay  M, Aydin  N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis. 1991;23:3335. DOIPubMed
  8. Lightfoot  N, Scott  R, Turnbull  B. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med Bull. 1990;68(Suppl):958.
  9. Turnbull  PC, Sirianni  NM, LeBron  CI, Samaan  MN, Sutton  FN, Reyes  AE, MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol. 2004;42:362634. DOIPubMed
  10. Chen  Y, Succi  J, Tenover  FC, Koehler  TM. ß-lactamase genes of the penicillin-susceptible Bacillus anthracis Sterne strain. J Bacteriol. 2003;185:82330. DOIPubMed
  11. Materon  IC, Queenan  AM, Koehler  TM, Bush  K, Palzkill  T. Biochemical characterization of beta-lactamases Bla1 and Bla2 from Bacillus anthracis. Antimicrob Agents Chemother. 2003;47:20402. DOIPubMed
  12. Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep. 2001;50:90919.PubMed
  13. Athamna  A, Athamna  M, Abu-Rashed  N, Medlej  B, Bast  DJ, Rubinstein  E. Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother. 2004;54:4248. DOIPubMed
  14. Price  LB, Vogler  A, Pearson  T, Busch  JD, Schupp  JM, Keim  P. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob Agents Chemother. 2003;47:23625. DOIPubMed
  15. Choe  CH, Bouhaouala  SS, Brook  I, Elliot  TB, Knudson  GB. In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne. Antimicrob Agents Chemother. 2000;44:1766. DOIPubMed
  16. Brook  I, Elliott  TB, Pryor  HI, Sautter  TE, Gnade  BT, Thaker  JH, In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents. 2001;18:55962. DOIPubMed
  17. Friedlander  AM, Welkos  SL, Pitt  ML, Ezzell  JW, Worsham  PL, Rose  KJ, Postexposure prophylaxis against experimental inhalation anthrax. [s]. J Infect Dis. 1993;167:123943.PubMed
  18. Department of Health and Human Services. Food and Drug Administration. Prescription Drug Products: Doxycycline and penicillin G procaine administration for inhalational anthrax (post-exposure). Fed Regist. 2001;66:5567982.
  19. Davis  H, McGoodwin  E, Reed  TG. Anaphylactoid reactions reported after treatment wth ciprofloxacin. Ann Intern Med. 1989;111:10413.PubMed
  20. Shapiro  LE, Knowles  SR, Shear  NH. Comparative safety of tetracycline, minocycline and doxycycline. Arch Dermatol. 1997;133:122430. DOIPubMed
  21. Tierney  BC, Martin  SW, Franzke  LH, Marano  N, Reissman  DB, Louchart  RD, Serious adverse events among participants in the Centers for Disease Control and Prevention's anthrax vaccine and antimicrobial availability program for persons at risk for bioterrorism-related inhalational anthrax. Clin Infect Dis. 2003;37:90511. DOIPubMed
  22. Ortho-McNeil Pharmaceutical. Product insert, Levaquin (Levofloxacin) tablets, 2004.
  23. Weingartner  L, Sitka  U, Patsch  R, Thiemann  HH, Bromme  W, Richter  I. Amoxicillin in paediatrics, with special reference to its excretion into bronchial secretion. Int J Clin Pharmacol Ther Toxicol. 1980;18:1859.PubMed
  24. Cook  PJ, Andrews  JM, Woodcock  J, Wise  R, Honeybourne  D. Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection. Thorax. 1994;49:11348.PubMed
  25. Meselson  M, Guillemin  J, Hugh-Jones  M, Langmuir  A, Popova  I, Shelokov  A, The Sverdlovsk anthrax outbreak of 1979. Science. 1994;266:12028. DOIPubMed
  26. Vietri  NJ, Purcell  BK, Lawler  JV, Leffel  EK, Rico  P, Gamble  CS, Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci U S A. 2006;103:78136. DOIPubMed
  27. Pittman  PR, Norris  SL, Barrera Oro  JG, Bedwell  D, Cannon  TL, McKee  KT Jr. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine. 2006;24:365460. DOIPubMed
  28. Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep. 2001;50:9418.PubMed
  29. Mayer  TA, Morrison  A, Bersoff-Matcha  S, Druckenbrod  G, Murphy  C, Howell  J, Inhalational anthrax due to bioterrorism: would current Centers for Disease Control and Prevention guidelines have identified the 11 patients with inhalational anthrax from October through November 2001? Clin Infect Dis. 2003;36:127583. DOIPubMed
  30. Hupert  N, Bearman  G, Mushlin  A, Callahan  M. Accuracy of screening for inhalational anthrax after a bioterrorist attack. Ann Intern Med. 2003;139:33745.PubMed
  31. Sejvar  JJ, Tenover  FC, Stephens  DS. Management of anthrax meningitis. Lancet Infect Dis. 2005;5:28795. DOIPubMed
  32. Fritz  DL, Jaax  NK, Lawrence  WB, Davis  KJ, Pitt  ML, Ezzell  JW, Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest. 1995;73:691702.PubMed
  33. Jernigan  JA, Stephens  DS, Ashford  DA, Omenaca  C, Topiel  MS, Galbraith  M, Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis. 2001;7:93344.PubMed
  34. Holty  JE, Bravata  DM, Liu  HRAO. K.M. M, Owens DK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med. 2006;144:27080.PubMed
  35. Abramova  FA, Grinberg  LM, Yampolskaya  OV, Walker  DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A. 1993;90:22914. DOIPubMed
  36. Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep. 2001;50:90919.PubMed
  37. Brachman  P, Gold  H, Plotkin  S, Fekety  F, Werrin  M, Ingraham  N. Field evaluation of a human anthrax vaccine. Am J Public Health. 1962;52:63245.
  38. Knudson  GB. Treatment of anthrax in man: history and current concepts. Mil Med. 1986;151:717.PubMed
  39. Committee on Obstetric Practice. ACOG Committee Opinion number 268, February 2002. Management of asymptomatic pregnant or lactating women exposed to anthrax. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2002;99:3668. DOIPubMed
  40. Wiesen  AR, Littell  CT. Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US Army women. JAMA. 2002;287:155660. DOIPubMed

Main Article

Page created: July 16, 2010
Page updated: July 16, 2010
Page reviewed: July 16, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external